1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Working Toward A Cure: Janssen’s Multiple Myeloma Strategy

T-cell Engagers, CAR-T Therapy Build On Darzalex Success

 
• By Mandy Jackson

Janssen’s Mark Wildgust explained how the Johnson & Johnson subsidiary is pushing forward with novel therapeutics and combination regimens with the goal of eliminating myeloma in the first line.

Multiple myeloma concept on tablet screen with stethoscope
Janssen will build on its Darzalex franchise with CAR-T therapies, bispecifics and more • Source: Alamy

Multiple myeloma is all about combination regimens, but Janssen Pharmaceutical Cos. is bringing forward new therapies with promising single-agent activity with the goal of shaking up existing regimens and curing patients early in their disease. Mark Wildgust, vice president of global medical affairs in Janssen’s oncology group, explained to Scrip how the Johnson & Johnson subsidiary is building on its success with the CD38 inhibitor Darzalex (daratumumab) with curative regimens in mind.

Darzalex and its subcutaneously administered version Darzalex Faspro are approved in six different multiple myeloma indications, including as a monotherapy...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 
• By Andrew McConaghie

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By Manas Mishra

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 
• By Jessica Merrill

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

More from R&D

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 
• By Jessica Merrill

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Obesity Beyond GLP-1s: Amylins – The Next Frontier

 
• By Aakash Babu

In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.